Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.


“MedCity is invaluable among the many sources of industry reporting because the team endeavor to bring the truly new, and innovative opportunities and developments to light.”

Ken Kirby, President, Transdermal Delivery Solutions Corp


Sign up for our daily newsletter


Migraine patch developer reduces workforce in cost cutting measure

7:17 pm by | 0 Comments

The new CEO of NuPathe (NASDAQ:PATH) followed through on his pledge to cut costs at the biopharmaceutical startup by reducing its workforce by half, according to documents filed with the Securities and Exchange Commission.

The cuts, which would amount to the loss of 18 jobs from a staff of 43, come just three months before a PDUFA date for NP101 when the US Food and Drug Administration is scheduled to give a thumbs up or thumbs down for the transdermal drug delivery patch to treat migraine headaches. The staff reduction is part of a series of cost-cutting measures the company has initiated to meet the conditions of a financing deal for $28 million to give the company enough to operate through the fourth quarter of next year.

In July Armando Anido told MedCity News his number one priority was securing cash to ptovide sufficient resources to launch of the migraine patch.

Anido replaced Jane Hollingsworth, who started the company in 2006, and had previously suceeded her at Auxilium Pharmaceuticals (NASDAQ: AUXL).

Advertisement

In addition to the job cuts, the company is also delaying the fling of an investigational new drug application for bipolar disorder and schizophrenia until it can find a partner to co-develop the drug.

The cuts come roughly one year after NuPathe received a complete response letter for its migraine patch. The company addressed concerns raised by the letter earlier this year.

The Zelrix transdermal patch transmits sumatriptan with an electrical charge through the skin in a drug-delivery method known as iontophoresis. The delivery method was selected because nausea is one of the symptoms migraine headache sufferers experience, and can make oral medication a challenge.

[Photo from Bigstock Photo]

 

 

 

 

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Stephanie Baum

By Stephanie Baum

Stephanie Baum is the East Coast Innovation Reporter for MedCityNews.com. She enjoys covering healthcare startups across health IT, drug development and medical devices and innovations deployed to improve medical care. She graduated from Franklin & Marshall College in Pennsylvania and has worked across radio, print and video. She's written for The Christian Science Monitor, Dow Jones & Co. and United Business Media.
Visit website | More posts by Author

0 comments